Search Results
May 21, 2026, 19:49 ET 2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
clinical trials globally, led by a pivotal Phase II study in China in previously untreated acral and mucosal melanoma and a global multi-regional Phase III trial in immunotherapy-resistant squamous NSCLC. In parallel, multiple Phase Ib/II trials are evaluating IBI363 in NSCLC and CRC including the first-line
More news about: Innovent Biologics
May 21, 2026, 17:18 ET INVESTOR DEADLINE TUESDAY: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law
with Anktiva to be cancer-free for the long term, when this has not been demonstrated"; (ii) the claim that Anktiva is a cancer vaccine was false; and (iii) ImmunityBio's Executive Chairman and Global Scientific and Medical Officer, defendant Dr. Patrick Soon-Shion, materially overstated Anktiva's capabilities.The
More news about: Robbins Geller Rudman & Dowd LLP
May 21, 2026, 17:00 ET New Clinical Data for Izalontamab Brengitecan and Novel ADC Pipeline to be Presented at ASCO 2026
first randomized, Phase III study evaluating iza-bren versus physician's choice of chemotherapy in unresectable locally advanced or metastatic triple-negative breast cancer patients in ChinaSafety and efficacy data from a randomized, open label, multi-center, Phase III study evaluating iza-bren
More news about: SystImmune, Inc.
May 21, 2026, 17:00 ET Boehringer Ingelheim's oncology portfolio shows strong promise across multiple cancers at ASCO 2026
chemotherapy is being evaluated as a first-line treatment vs. atezolizumab plus SOC chemotherapy in a Phase III trial for patients with ES-SCLC (DAREON®-LUNG-1).15 Additionally, a Phase III trial is ongoing to evaluate obrixtamig in combination with SOC chemotherapy vs. chemotherapy alone as first-line
More news about: Boehringer Ingelheim
May 21, 2026, 16:05 ET CAE reports fourth quarter and full fiscal year 2026 results and targets significant cost savings and profitability growth as part of transformation plan
competitive advantage, (ii) strengthening capital discipline by prioritizing higher-return investments and optimizing the commercial training network, and (iii) improving operational performance through better integration of people, processes, and technology. Together, these actions are intended to position
More news about: CAE Inc.
May 21, 2026, 16:01 ET Workday Announces Fiscal 2027 First Quarter Financial Results
infrastructure operations; (ii) service outages, delays in the deployment of our applications, and the failure of our applications to perform properly; (iii) competitive factors, including pricing pressures, industry consolidation, entry of new competitors and new applications, advancements in technology,
More news about: Workday, Inc.
May 21, 2026, 15:49 ET Electrolux Group announces terms for the fully underwritten rights issue of SEK 9,062 million
(Financial Promotion) Order 2005, as amended (the "Order"), (ii) are high net worth entities falling within Article 49(2)(a) to (d) of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets
More news about: Electrolux Group
May 21, 2026, 15:45 ET Electrolux Group announces terms for the fully underwritten rights issue of SEK 9,062 million
(Financial Promotion) Order 2005, as amended (the "Order"), (ii) are high net worth entities falling within Article 49(2)(a) to (d) of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets
More news about: Electrolux Group
May 21, 2026, 15:25 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
action]On March 13, 2026, Immutep issued a press release "announc[ing] that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial
More news about: Pomerantz LLP
May 21, 2026, 15:10 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Pinterest, Inc. and Certain Officers - PINS
States ("U.S.") tariffs on the macroeconomic environment in which the Company operated, including the foreseeable impact on its advertising partners; (iii) the impact of the foregoing on Pinterest's advertising revenues was significant enough that Pinterest was facing and/or likely to face an imminent restructuring;
More news about: Pomerantz LLP
May 21, 2026, 15:10 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA
ALLELE study, made it unlikely that the FDA would approve the tabelecleucel BLA; (ii) accordingly, tabelecleucel's regulatory prospects were overstated; (iii) the aforementioned manufacturing issues also subjected Atara to a heightened risk of regulatory scrutiny, as well as jeopardized its ongoing clinical
More news about: Pomerantz LLP
May 21, 2026, 15:10 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Upstart Holdings, Inc. and Certain Officers - UPST
performing its risk-separation processes; (ii) accordingly, Model 22's overall accuracy and propensity to increase loan approval rates was overstated; (iii) Model 22's overly conservative assessment of credit and macroeconomic conditions was having a significant negative impact on Upstart's revenue results,
More news about: Pomerantz LLP
May 21, 2026, 15:10 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC
manipulation; (ii) the resulting volatility in the market for the Company's ordinary shares exposed Regencell's investors to significant financial risk; (iii) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant
More news about: Pomerantz LLP
May 21, 2026, 15:10 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Graphic Packaging Holding Company and Certain Former Officers - GPK
and severity of the foregoing issues, which were likely to, and did, have a material negative impact on the Company's business and financial results; (iii) Defendants likewise overstated the strength and sustainability of the Company's business model and operations, as well as its ability to weather ongoing
More news about: Pomerantz LLP
May 21, 2026, 15:10 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Babcock & Wilcox Enterprises, Inc. and Certain Officers - BW
Applied Digital did not need the products and services that B&W would purportedly supply pursuant to the Power Generation LNTP and Contract; (iii) the foregoing, at the very least, would raise questions about the parties' actual intent behind entering into the Power Generation LNTP and Contract,
More news about: Pomerantz LLP
May 21, 2026, 15:10 ET Pomerantz Law Firm Announces the Filing of a Class Action Against ServBanc Holdco, Inc., ServBank, National Association, IF Bancorp, Inc., and its Board of Directors - IROQ
and Special Dividend were misleading insofar as they overstated the likelihood that IF Bancorp shareholders would receive the Special Dividend; and (iii) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable
More news about: Pomerantz LLP
May 21, 2026, 13:53 ET A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC
accounts. We strongly urge all shareholders to vote FOR all three DOMA nominees, Christopher Dennis, MD, MBA, FAPA, Oliver Benton "Ben" Curtis III, and Eric de Armas, using the WHITE proxy card in advance of the June 9, 2026, annual meeting. The DOMA nominees will have only one guiding
More news about: DOMA Perpetual
May 21, 2026, 13:41 ET TEDCO Announces the FY27 Board of Directors
includes: Chair, David Tohn, BTS Software Solutions; Vice Chair, Nona Minnifield Cheeks, Innovatyr, LLC; Secretary, Thomas Bundy III, Lawrence & Bundy; Treasurer, William Roberts, Significance, Inc.; Assistant Treasurer, Eben Smith, Three|E Consulting Group;
More news about: TEDCO
May 21, 2026, 13:33 ET Lysine Market Expands as Precision Animal Nutrition Gains Global Momentum | CAGR 6.4%
Saffron Market by Grade (Grade I, Grade II, Grade III, Grade IV), Form (Stigma, Powder, Liquid, Petals, Stamen), Application (Food & Beverages, Pharmaceuticals, Cosmetics & Personal Care), Distribution
More news about: Persistence Market Research Pvt. Ltd.
May 21, 2026, 12:06 ET NYSE: SES CLASS ACTION NOTICE: Berger Montague Encourages SES AI Corporation (NYSE: SES) Investors to Inquire About a Securities Fraud Class Action
circular counterparties; (ii) the Company faced operational constraints that undermined its ability to generate the revenues it had projected; and (iii) underlying demand for SES AI's products was deteriorating.On December 9, 2025, Wolfpack Research published a report alleging that SES AI had
More news about: Berger Montague
May 21, 2026, 11:03 ET Coastal Mississippi Heats Up with Sun-Soaked Escapes and Unforgettable Events
100 Men Hall's premier annual event celebrating the one-of-a-kind, greatest piano player the region has ever produced, James Carroll Booker III. September 4-6, Bay St. Louis, MS.
More news about: Coastal Mississippi
May 21, 2026, 10:04 ET Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Breast03) of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan
More news about: Kelun-Biotech
May 21, 2026, 09:07 ET Leading Security Technology Provider Launches Advanced Detection Solutions for Law Enforcement, Correctional, Healthcare, and K-12 School Facilities
design that includes non-magnetic AISI 316L stainless steel and high-impact reinforced plastics.The MSDW Plus can operate in MRI Zones I, II, or III and features a local FIFO logger capable of recording up to 100,000 events. Designed to be quick and easy to use with limited staff training required,
More news about: CEIA USA
May 21, 2026, 09:06 ET PINS EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Pinterest (PINS) Investors of Securities Class Action Deadline on May 29, 2026
reallocating resources to AI-focused roles and teams that drive AI adoption and execution, (ii) prioritizing AI powered products and capabilities, and (iii) accelerating the transformation of its sales and go-to-market approach."On this news, Pinterest's stock price fell $2.49 per share, or 9.61%,
More news about: Faruqi & Faruqi, LLP
May 21, 2026, 09:00 ET POMERANTZ LLP ANNOUNCES NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION INVOLVING SOLAREDGE TECHNOLOGIES, INC.
Settlement as fair, reasonable, and adequate; (ii) dismiss the Action with prejudice as provided in the Stipulation of Settlement, dated April 21, 2026; (iii) approve the proposed Plan of Allocation for distribution of the proceeds of the Settlement (the "Net Settlement Fund") to Settlement Class Members;
More news about: Pomerantz LLP